Redox regulation following cardiac ischemia and reperfusion

Coronary Artery Disease

Volumn 14, Issue 2, 2003, Pages 123-133

  Marczin, Nándor ^a   Bundy, Ruth E ^a   Hoare, Ginette S ^a   Yacoub, Magdi ^a  

^a HAREFIELD HOSPITAL   (United Kingdom)

Author keywords

Endothelium; MAPK; NF B; Oxidants; Oxidative stress; Redox regulation; Smooth muscle

Indexed keywords

CYTOKINE; MITOGEN ACTIVATED PROTEIN KINASE; REACTIVE OXYGEN METABOLITE; STRESS ACTIVATED PROTEIN KINASE;

BLOOD VESSEL WALL; CONTROLLED STUDY; CYTOKINE PRODUCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HUMAN; INFLAMMATION; LEUKOCYTE; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; TRANSCRIPTION REGULATION;

APOPTOSIS; CELL SURVIVAL; HUMANS; MYOCARDIAL ISCHEMIA; NF-KAPPA B; OXIDATION-REDUCTION; OXIDATIVE STRESS; REPERFUSION INJURY; TRANSCRIPTION FACTORS;

EID: 0038746702     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019501-200304000-00005     Document Type: Review

References (69)

1. Pinsky DJ, Naka Y, Chowdhury NC, Liao H, Oz MC, Michler RE. The nitric oxide/cyclic GMP pathway in organ transplantation: critical role in successful lung preservation. Proc Natl Acad Sci USA 1994; 91:12086-12090.
2. Boehler A, Kesten S, Weder W, Speich R. Bronchiolitis obliterans after lung transplantation: a review. Chest 1998; 114:1411-1426.
3. Serrick C, Giaid A, Reis A, Shennib H. Prolonged ischemia is associated with more pronounced rejection in the lung allograft. Ann Thorac Surg 1997; 63:202-208.
4. Chakraborti S, Chakraborti T. Oxidant-mediated activation of mitogen-activated protein kinases and nuclear transcription factors in the cardiovascular system: a brief overview. Cell Signal 1998; 10:675-683.
5. Roebuck KA. Oxidant stress regulation of IL-8 and ICAM-1 gene expression: differential activation and binding of the transcription factors AP-1 and NF-kappaB [review]. Int J Mol Med 1999; 4:223-230.
6. Ichikawa H, Flores S, Kvietys PR, Wolf RE, Yoshikawa T, Granger DN, Aw TY. Molecular mechanisms of anoxia/reoxygenation-induced neutrophil adherence to cultured endothelial cells. Circ Res 1997; 81:922-931. This study identifies two distinct phases of neutrophil-endothelial cell interaction following ischemia-reperfusion: an early phase occurring 30 min after reperfusion driven by xanthine oxidase and hydrogen peroxide and a second phase occurring at 240 min.
7. Nathan CF. Neutrophil activation on biological surfaces. Massive secretion of hydrogen peroxide in response to products of macrophages and lymphocytes. J Clin Invest 1987; 80:1550-1560.
8. Chandrasekar B, Colston JT, Geimer J, Cortez D, Freeman GL. Induction of nuclear factor kappaB but not kappaB-responsive cytokine expression during myocardial reperfusion injury after neutropenia. Free Radic Biol Med 2000; 28:1579-1588.
9. Simpson PJ, Todd RF III, Mickelson JK, Fantone JC, Gallagher KP, Lee KA. Sustained limitation of myocardial reperfusion injury by a monoclonal antibody that alters leukocyte function. Circulation 1990; 81:226-237.
10. Jones SP, Trocha SD, Strange MB, Granger DN, Kevil CG, Bullard DC, Lefer DJ Leukocyte and endothelial cell adhesion molecules in a chronic murine model of myocardial reperfusion injury. Am J Physiol Heart Circ Physiol 2000; 279:H2196-H2201.
11. Palazzo AJ, Jones SP, Girod WG, Anderson DC, Granger DN, Lefer DJ. Myocardial ischemia-reperfusion injury in CD18- and ICAM-1-deficient mice. Am J Physiol 1998; 276: H2300-H2307.
12. Zhao ZQ, Lefer DJ, Sato H, Hart KK, Jefforda PR, Vinten-Johansen J. Monoclonal antibody to ICAM-1 preserves postischemic blood flow and reduces infarct size after ischemia-reperfusion in rabbit. J Leukoc Biol 1997; 62:292-300.
13. Brand K, Page S, Rogler G, Bartsch A, Brandl R, Knuechel R, et al. Activated transcription factor nuclear factor-κB is present in the atherosclerotic lesion. J Clin Invest 1996; 97:1715-1722.
14. Fan H, Sun B, Gu Q, Lafond-Walker A, Cao S, Becker LC. Oxygen radicals trigger activation of NF-κB and AP-1 and upregulation of ICAM-1 in reperfused canine heart. Am J Physiol Heart Circ Physiol 2002; 282:H1778-H1786.
15. Chandrasekar B, Smith JB, Freeman GL. Ischemia-reperfusion of rat myocardium activates nuclear factor-KappaB and induces neutrophil infiltration via lipopolysaccharidednduced CXC chemokine. Circulation 2001; 103:2296-2302.
16. Sawa Y, Morishita R, Suzuki K, Kagisaki K, Kaneda Y, Maeda K, et al. A novel strategy for myocardial protection using in vivo transfection of cis element 'decoy' against NFkappaB binding site: evidence for a role of NFkappaB in ischemia-reperfusion injury. Circulation 1997; 96:1I-4. Important study suggesting that Nuclear Factor-κB (NF-κB) plays a significant role in ischemia-reperfusion injury. Also present is a method, using in-vivo gene transfection of cis element decoy against NF-κB binding site, for a novel and future strategy for myocardial protection.
17. Morishita R, Higaki J, Tomita N, Ogihara T. Application of transcription factor 'decoy' strategy as means of gene therapy and study of gene expression in cardiovascular disease. Circ Res 1998; 82:1023-1028.
18. Schreck R, Rieber P, Baeuerle PA. Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-κB transcription factor and HIV-1. EMBO J 1991; 10:2247-2258. This paper demonstrates that NF-κB activation in a human T cell line induced by a variety of diverse stimuli could be inhibited by the antioxidant N-acetyl-I-cysteine. The authors suggest that all the agents tested, whilst originally thought to activate NF-κB by distinct intracellular pathways, may in fact share common mechanisms and suggest that reactive oxygen intermediates serve as the widely used second messenger in the activation of NF-κB
19. Bowie A, O'Neill LA. Oxidative stress and nuclear factor-κB activation: a reassessment of the evidence in the light of recent discoveries. Biochem Pharmacol 2000; 59:13-23. In this review the authors critically examine the evidence for the universal role of oxidative stress in NF-κB activation. They find that the majority of the data in support of the oxidative stress model of NF-κB activation are specific to a stimulus in a cell line. This paper concludes that the evidence does not point to a central role for reactive oxygen species (ROS) and suggests that it is now important when proposing a role of ROS in a pathway to identify the particular kinase or adapter molecule that is redox modulated. These authors stress the need to treat individual pathways of NF-κB activation as distinct and suggest that the role of oxidative stress is the exception rather than the rule.
20. Rahman A, Kefer J, Bando M, Niles WD, Malik AB. E-selectin expression in human endothelial cells by TNF-alpha-induced oxidant generation and NF-kappaB activation. Am J Physiol 1998; 275:L533-L544.
21. 2 in NF-kappaB activation by either cytokine in both primary and transformed endothelial cells. J Biol Chem 1997; 272:25941-25950.
22. Imbert V, Rupec RA, Livolsi A, Pahl HL, Traenckner EB, Mueller-Dieckmann C, et al. Tyrosine phosphorylation of IκB-α activates NF-κB without proteolytic degradation of IκB-α. Cell 1996; 86:787-798.
23. Schoonbroodt S, Ferreira V, Best-Belpomme M, Boelaert JR, Legrand-Poels S, Korner M, Piette J. Crucial role of the amino-terminal tyrosine residue 42 and the carboxyl-terminal PEST domain of I kappa B alpha in NF-kappa B activation by an oxidative stress. J Immunol 2000; 164:4292-4300.
24. Matthews JR, Wakasugi N, Virelizier JL, Yodoi J, Hay RT. Thioredoxin regulates the DNA binding activity of NF-kappa B by reduction of a disulphide bond involving cysteine 62. Nucleic Acids Res 1992; 20:3821-3830. This is one of the first publications identifying the necessity of the conserved cysteine residue in the DNA binding loop of NF-κB p50. The authors use purified NF-κB proteins and site-directed mutagenesis to identify cysteine 62 of p50 as being the important residue. Substitution of this cysteine for a serine decreased the DNA activity and rendered the protein insensitive to thiol modifying agents. The authors were also able to conclude that thioredoxin stimulates DNA binding of NF-κB by reduction of a disulphide bond involving cysteine 62.
25. Hirota K, Murata M, Sachi Y, Nakamura H, Takeuchi J, Mori K, Yodoi J. Distinct roles of thioredoxin in the cytoplasm and in the nucleus. A two-step mechanism of redox regulation of transcription factor NF-κB. J Biol Chem 1999; 274:27891-2789. This paper demonstrates that thioredoxin in the cytoplasm suppresses the degradation of IκBα, whilst thioredoxin in the nucleus enhances the DNA binding activity of NF-κB.
26. Takeuchi J, Hirota K, Itch T, Shinkura R, Kitada K, Yodoi J, et al. Thioredoxin inhibits TNF- or interleukin-1-induced NF-κB activation at a level upstream of NF-κB-inducing kinase. Antioxid Redox Signal 2000; 2:83-92.
27. Halle AA 3rd, Wilson RF, Massin EK, Bourge RC, Stadius ML, Johnson MR, et al. Coronary angioplasty in cardiac transplant patients. Results of a multicenter study. Circulation 1992; 86:458-462.
28. Abe J, Baines CP, Berk BC. Role of mitogen-activated protein kinases in ischemia and reperfusion injury: the good and the bad [editorial; comment]. Circ Res 2000; 86:607-609. This interesting review highlights multiple roles of Mitogen Activated Protein Kinase (MAPK) related to myocardial ischemia.
29. 2 for platelet-derived growth factor signal transduction. Science 1995; 270:296-299. A key paper demonstrating the involvement of reactive oxygen species in mediation of growth factor-induced cell signalling
30. 2 and suggesting the cytoprotective role of ERK Mitogen Activated Protein Kinase (MAPK).
31. Ushio-Fukai M, Alexander RW, Akers M, Griendling KK. p38 Mitogen-activated protein kinase is a critical component of the redox-sensitive signaling pathways activated by angiotensin II. Role in vascular smooth muscle cell hypertrophy. J Biol Chem 1998; 273:15022-15029.
32. - in vascular smooth muscle cells. Circ Res 1995; 77:29-36. Important study to demonstrate that distinct reactive oxygen species induce differential activation of Mitogen Activated Protein Kinase (MAPK) subfamilies.
33. Bhunia AK, Han H, Snowden A, Chatterjee S. Redox-regulated signaling by lactosylceramide in the proliferation of human aortic smooth muscle cells. J Biol Chem 1997; 272:15642-15649.
34. 2-induced increase in permeability across endothelial cell junctions.
35. Yue TL, Wang C, Gu JL, Ma XL, Kumar S, Lee JC, et al. Inhibition of extracellular signal-regulated kinase enhances ischemia/reoxygenation-induced apoptosis in cultured cardiac myocytes and exaggerates reperfusion injury in isolated perfused heart. Circ Res 2000; 86:692-699. This study suggests that a dynamic balance in activities of antiapoptotic ERK and proapoptotic p38 and JNK determines the fate of the cell including global function after reperfusion and apoptosis.
36. Chin BY, Petrache I, Choi AM, Choi ME. Transforming growth factor beta1 rescues serum deprivation-induced apoptosis via the mitogen-activated protein kinase (MAPK) pathway in macrophages. J Biol Chem 1999; 274:11362-11368. In this study, transforming growth factor appears to rescue murine macrophages from apoptosis via an ERK-dependent mechanism.
37. Mehrhof FB, Muller FU, Bergmann MW, Li P, Wang Y, Schmitz W, et al. In cardiomyocyte hypoxia, insulin-like growth factor-induced antiapoptotic signaling requires phosphatidylinositol-3-OH-kinase-dependent and mitogen-activated protein kinase-dependent activation of the transcription factor cAMP response element-binding protein. Circulation 2001; 104:2088-2094.
38. Iwai-Kanai E, Hasegawa K, Fujita M, Araki M, Yanazume T, Adachi S, Sasayama S, et al. Basic fibroblast growth factor protects cardiac myocytes from iNOS-mediated apoptosis. J Cell Physiol 2002; 190:54-62.
39. Kim HT, Tasca S, Qiang W, Wong PK, Stoica G. Induction of p53 accumulation by Moloney murine leukemia virus-ts1 infection in astrocytes via activation of extracellular signal-regulated kinases 1/2. Lab Invest 2002; 82:693-702.
40. Cuda G, Paterno R, Ceravolo R, Candigliota M, Perrotti N, Perticone F, et al. Protection of human endothelial cells from oxidative stress: role of Ras-ERK1/2 signaling. Circulation 2002; 106:968-974.
41. 2 infusion. P38 inhibition decreased tomour necrosis factor production, cardiomyocyte death and myocardial dysfunction.
42. Fijen JW, Tulleken JE, Kobold AC, de Boer P, van der Wert TS, Ligtenberg JJ, et al. Inhibition of p38 mitogen-activated protein kinase: dose-dependent suppression of leukocyte and endothelial response after endotoxin challenge in humans. Crit Care Med 2002; 30:841-845. An in-vivo study in humans showing the beneficial effect of administration of an oral p38 inhibitor in preventing neutrophil and endothelial adhesion molecule activation after endotoxin infusion.
43. Dougherty CJ, Kubasiak LA, Prentice H, Andreka P, Bishopric NH, Webster KA. Activation of c-Jun N-terminal kinase promotes survival of cardiac myocytes after oxidative stress. Biochem J 2002; 362:561-571. An important study to show that JNK might have cytoprotective role depending on cell type and stimulus. Also contains critical discussion about this important controversy.
44. Minamino T, Yujiri T, Papst PJ, Chan ED, Johnson GL, Terada N. MEKK1 suppresses oxidative stress-induced apoptosis of embryonic stem cell-derived cardiac myocytes. Proc Natl Acad Sci USA 1999; 96:15127-15132.
45. Andreka P, Zang J, Dougherty C, Slepak TI, Webster KA, Bishopric NH. Cytoprotection by Jun kinase during nitric oxide-induced cardiac myocyte apoptosis. Circ Res 2001; 88:305-312. A study contradicting the universal cytotoxic role of JNK. Cardiomyocyte mutants of JNK showed that JNK mediates NO-induced apoptosis and that early, transient activation of JNK by low NO concentrations apparently delays and reduces apoptosis.
46. Shklyaev SS, Namba H, Mitsutake N, Alipov G, Nagayama Y, Maeda S, et al. Transient activation of c-Jun NH2-terminal kinase by growth factors influences survival but not apoptosis of human thyrocytes. J Neurosci 2001; 11:629-636.
47. Ham J, Eilers A, Whitfield J, Neame SJ, Shah B. c-Jun and the transcriptional control of neuronal apoptosis. Biochem Pharmacol 2000; 60:1015-1021.
48. Marais E, Genade S, Strijdom H, Moolman JA, Lochner A. p38 MAPK activation triggers pharmacologically-induced beta-adrenergic preconditioning, but not ischaemic preconditioning. J Mot Cell Cardiol 2001; 33:2157-2177.
49. Zhao TC, Taher MM, Valerie KC, Kukreja RC. p38 Triggers late preconditioning elicited by anisomycin in heart: involvement of NF-kappaB and iNOS. Circ Res 2001; 89:915-922.
50. Fryer RM, Hsu AK, Gross GJ. ERK and p38 MAP kinase activation are components of opioid-induced delayed cardioprotection. Basic Res Cardiol 2001; 96:136-142.
51. Marais E, Genade S, Huisamen B, Strijdom JG, Moolman JA, Lochner A. Activation of p38 MAPK induced by a multi-cycle ischaemic preconditioning protocol is associated with attenuated p38 MAPK activity during sustained ischaemia and repeffusion. J Mol Cell Cardiol 2001; 33:769-778.
52. Mocanu MM, Baxter GF, Yue Y, Critz SD, Yellon DM. The p38 MAPK inhibitor, SB203580, abrogates ischaemic preconditioning in rat heart but timing of administration is critical. Basic Res Cardiol 2000; 96:472-478.
53. Scares MP, Usheva A, Brouard S, Berberat PC, Gunther L, Tobiasch E, Bach FH. Modulation of endothelial cell apoptosis by heme oxygenase-1-derived carbon monoxide. Antioxid Redox Signal 2002; 4:321-329.
54. Lee TS, Chau LY. Heme oxygenase-1 mediates the anti-inflammatory effect of interleukin-10 in mice. Nat Med 2002; 8:240-246.
55. Behr TM, Nerurkar SS, Nelson AH, Coatney RW, Woods TN, Sutpizio A, et al. Hypertensive end-organ damage and premature mortality are p38 mitogen-activated protein kinase-dependent in a rat model of cardiac hypertrophy and dysfunction. Circulation 2001; 104:1292-1298.
56. Wang Y, Huang S, Sah VP, Ross J Jr, Brown JH, Han J, Chien KR. Cardiac muscle cell hypertrophy and apoptosis induced by distinct members of the p38 mitogen-activated protein kinase (MAPK) family. J Biol Chem 1998; 273:2161-2168. This study provides the first evidence in any cell system for divergent physic-logical functions for different members of the p38 MAP kinase family. The direct involvement of p38 pathways in cardiac hypertrophy and apoptosis suggests a significant role for p38 signaling in the pathophysiology of heart failure.
57. Saurin AT, Martin JL Heads RJ, Foley C, Mockridge JW, Wright MJ, et al. The role of differential activation of p38-mitogen-activated protein kinase in preconditioned ventricular myocytes. FASEB J 2000; 14:2237-2246.
58. Martin JL, Avkiran M, Quinlan RA, Cohen P, Marber MS. Antiischemic effects of SB203580 are mediated through the inhibition of p38alpha mitogen-activated protein kinase: evidence from ectopic expression of an inhibition-resistant kinase. Circ Res 2001; 89:750-752.
59. Hagemann C, Blank JL. The ups and downs of MEK kinase interactions. Cell Signal 2001; 13:863-875. This review summarizes current knowledge concerning the regulation and function of MEKK family members, with particular emphasis on those factors capable of directly interacting with distinct MEKK isoforms.
60. Burack WR, Shaw AS. Signal transduction: hanging on a scaffold. Curr Opin Cell Biol 2000; 12:211-216. Interesting review of recent literature contributing to the concept that scaffolding proteins may play profound roles in multicomponent signal transduction systems.
61. Chen Z, Oberley TD, Ho Y, Chua CC, Siu B, Hamdy RC et al. Overexpression of CuZnSOD in coronary vascular cells attenuates myocardial ischemia/reperfusion injury. Free Radic Biol Med 2000; 29:589-596.
62. Wang P, Chen H, Qin H, Sankarapandi S, Becher MW, Wong PC, Zweier JL. Overexpression of human copper, zinc-superoxide dismutase (SOD1) prevents postischemic injury. Proc Natl Acad Sci USA 1998; 96:4556-4560.
63. Yoshida T, Watanabe M, Engelman DT, Engelman RM, Schley JA, Maulik N, et al. Transgenic mice overexpressing glutathione peroxidase are resistant to myocardial ischemia reperfusion injury. J Mol Cell Cardiol 1996; 28:1759-1767.
64. Ishibashi N, Weisbrot-Lefkowitz M, Reuhl K, Inouye M, Mirochnitchenko O. Modulation of chemokine expression during ischemia/reperfusion in transgenic mice overproducing human glutathione peroxidases. J Immunol 1999; 163:5666-5677.
65. Mirochnitchenko O, Prokopenko O, Palnitkar U, Kister I, Powell WS, Inouye M. Endotoxemia in transgenic mice overexpressing human glutathione peroxidases. Circ Res 2000; 87:289-295.
66. Yoshida T, Maulik N, Engelman RM, Ho YS, Magnenat JL, Rousou JA, et al. Glutathione peroxidase knockout mice are susceptible to myocardial ischemia repeffusion injury. Circulation 1997; 96:II-20.
67. Kokura S, Wolf RE, Yoshikawa T, Granger DN, Aw TY. Molecular mechanisms of neutrophil-endothelial cell adhesion induced by redox imbalance. Circ Res 1999; 84:516-524. This study identifies distinct differences between the two phases of neutrophil adhesion following ishemia-reperfusion with the first phase being reliant on preformed adhesion molecules and the second phase being driven by NF-κB- and Activating Protein -1 (AP-1) induced transcription of intercellular adhesion molecule-1 and E-selectin.
68. Ramires PR, Ji LL. Glutathione supplementation and training increases myocardial resistance to ischemia-reperfusion in vivo. Am J Physiol Heart Circ Physiol 2001; 281:H679-H688.
69. Arstall MA, Yang J, Stafford I, Betts WH, Horowitz JD. N-acetylcysteine in combination with nitroglycerin and streptokinase for the treatment of evolving acute myocardial infarction. Safety and biochemical effects. Circulation 1995; 92:2855-2862. An important clinical study showing that administration of the antioxidant N-acetyl-I-cysteine in combination with nitroglycerin (NTG) and streptokinase appeared to be safe for the treatment of evolving acute myocardial infarction and was associated with significantly less oxidative stress, a trend toward more rapid reperfusion and better preservation of left ventricular function.